(Q43593878)

English

Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases

scientific article published in April 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

author name string

Schepkens H

1

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Vanholder R

2

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Billiouw JM

3

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Lameire N

4

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

language of work or name

0 references

publication date

1 April 2001

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

American Journal of Medicine

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

110

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

438-441

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Captopril and spironolactone therapy for refractory congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900642-8

7 January 2021

Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900642-8

7 January 2021

Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900642-8

7 January 2021

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900642-8

7 January 2021

Life-threatening hyperkalaemia caused by angiotensin-converting enzyme-inhibitor and diuretics

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900642-8

7 January 2021

Iatrogenic hyperkalaemia--points to consider in diagnosis and management

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900642-8

7 January 2021

Posture as a contributing factor to beta-blockade-induced hyperkalaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900642-8

7 January 2021

Digitalis intoxication and hyperkalemia in hemodialysed patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900642-8

7 January 2021

Spironolactone and congestive heart-failure

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900642-8

7 January 2021

Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES])

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900642-8

7 January 2021

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900642-8

7 January 2021

Hyperkalaemia in diabetes: prevalence and associations

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900642-8

7 January 2021

Reversible hyperkalemia at the initiation of ACE inhibitors in a young diabetic patient with latent hyporeninemic hypoaldosteronism

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900642-8

7 January 2021

Hyperkalaemia in diabetes mellitus--potential hazards of coexisting hyporeninaemic hypoaldosteronism

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900642-8

7 January 2021

Angiotensin-converting enzyme inhibitors and renal function in heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900642-8

7 January 2021

Indomethacin-associated hyperkalemia in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900642-8

7 January 2021

Reversible acute renal insufficiency and hyperkalemia following indomethacin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900642-8

7 January 2021

Incidence of hyperkalaemia induced by indomethacin in a hospital population

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900642-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0002-9343(01)00642-8

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43593878&oldid=2101762040"